Lalwani Nikhil 4

What Happened

• Nikhil Lalwani, President & CEO and a director of ANI Pharmaceuticals (ANIP), had shares withheld to satisfy tax obligations tied to the vesting of restricted stock. Two withholding transactions were reported: 11,688 shares withheld on 2026-02-12 at $76.70 each ($896,470) and 10,298 shares withheld on 2026-02-14 at $77.36 each ($796,653). Combined, 21,986 shares were withheld, with a total value of approximately $1,693,123.
• This is a routine tax‑withholding disposition (not an open‑market sale) related to previously granted restricted stock.

Key Details

• Transaction dates and amounts:
  • 2026-02-12: 11,688 shares @ $76.70 = $896,470 (withheld)
  • 2026-02-14: 10,298 shares @ $77.36 = $796,653 (withheld)
• Total shares withheld: 21,986; total value ≈ $1,693,123.
• Shares owned after the transactions: not specified in the provided filing.
• Footnotes: Withholdings were made under Rule 16b-3 exemption in connection with vesting of restricted stock — F1 relates to 22,849 shares (grant reported 2025-02-18); F2 relates to 20,132 shares (grant reported 2024-02-16).
• Transaction code: F (payment of exercise price or tax liability / tax withholding).
• Filing: Report filed 2026-02-17 covering the 2026-02-12 and 2026-02-14 transactions. Form 4s are typically due within two business days; the 2026-02-12 withholding appears to have been filed one business day after that window.

Context

• These withholdings reflect tax withholding on vested restricted stock (cashless disposition by the company to cover taxes) and are generally considered routine administrative transactions, not direct market sales that signal buying or selling conviction.
• The filing notes the underlying grants were previously reported (dates above); no open‑market purchases or options exercises resulting in new share purchases are reported here.